✦ LIBER ✦

Trouble with tumor necrosis factor α inhibitors, not just tuberculosis

✍ Scribed by Tina Racunica; Dermot Cassidy; Flavia Cicuttini; Anthony Hall

Publisher: Wiley (John Wiley & Sons)
Year: 2010
Tongue: English
Weight: 116 KB
Volume: 62
Category: Article
ISSN: 2151-464X
DOI: 10.1002/acr.20245

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tuberculosis associated with therapy aga

Tuberculosis associated with therapy against tumor necrosis factor α

✍ Kevin L. Winthrop; Jeffrey N. Siegel; John Jereb; Zachary Taylor; Michael F. Iad 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 1 views

Evolution of dermatomyositis during ther

Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor

✍ Hall, Harald A. ;Zimmermann, Bernard 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

Association between the level of circula

Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at −308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor

✍ Hubert Marotte; Béatrice Arnaud; Jennifer Diasparra; Saloua Zrioual; Pierre Mios 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

Long-term treatment with methotrexate or

Long-term treatment with methotrexate or tumor necrosis factor α inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis

✍ Balandraud, Nathalie ;Guis, Sandrine ;Baptiste Meynard, Jean ;Auger, Isabelle ;R 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views

Treatment of rheumatoid arthritis with t

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report

✍ Juan J. Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín M 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 3 views

Individualized monitoring of drug bioava

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b